GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adbiotech Co Ltd (XKRX:179530) » Definitions » Debt-to-EBITDA

Adbiotech Co (XKRX:179530) Debt-to-EBITDA : -0.75 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Adbiotech Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Adbiotech Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩8,758 Mil. Adbiotech Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩3,682 Mil. Adbiotech Co's annualized EBITDA for the quarter that ended in Mar. 2024 was ₩-16,681 Mil. Adbiotech Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.75.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Adbiotech Co's Debt-to-EBITDA or its related term are showing as below:

XKRX:179530' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.07   Med: -3.02   Max: 3.6
Current: -5.95

During the past 5 years, the highest Debt-to-EBITDA Ratio of Adbiotech Co was 3.60. The lowest was -8.07. And the median was -3.02.

XKRX:179530's Debt-to-EBITDA is ranked worse than
100% of 277 companies
in the Biotechnology industry
Industry Median: 1.36 vs XKRX:179530: -5.95

Adbiotech Co Debt-to-EBITDA Historical Data

The historical data trend for Adbiotech Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adbiotech Co Debt-to-EBITDA Chart

Adbiotech Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
-3.02 -1.08 -8.07 3.60 -3.49

Adbiotech Co Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.41 -37.20 -3.63 -1.27 -0.75

Competitive Comparison of Adbiotech Co's Debt-to-EBITDA

For the Biotechnology subindustry, Adbiotech Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adbiotech Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adbiotech Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Adbiotech Co's Debt-to-EBITDA falls into.



Adbiotech Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Adbiotech Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9630.86 + 3979.235) / -3897.45
=-3.49

Adbiotech Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(8757.61 + 3681.634) / -16681.02
=-0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Adbiotech Co  (XKRX:179530) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Adbiotech Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Adbiotech Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Adbiotech Co (XKRX:179530) Business Description

Traded in Other Exchanges
N/A
Address
39, Geodudanji 1-gil, Dongnae-myeon, Gangwon-do, Chuncheon, KOR, 24398
Adbiotech Co Ltd is a life science company. It develops a vaccine and antibiotic-friendly substances such as IgY, Immunoglobulin in Yolk for human, animal and fish oral antibody products, and functional cosmetics and food additives. The company aim to develop Helico IgY, Cholesterol IgY, and Ulcerative Colitis natural product medicines.

Adbiotech Co (XKRX:179530) Headlines

No Headlines